Join
Live feed
·
PRReleasevia Quantisnow
Aridis Pharmaceuticals Inc. logo

Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARDS (Aridis Pharmaceuticals Inc.) and more on Quantisnow.